Schizophrenia is characterized by pathophysiological alterations of multiple neurotransmitter 31 systems such as dopaminergic, glutamatergic, GABA-ergic and serotonergic pathways. 32
Introduction

53
The pathophysiology of schizophrenia is understood to involve dysfunction of the 54 dopaminergic (Carlsson, 1988) , serotonergic (Meltzer and Massey, 2011) , glutamatergic 55 (Coyle, 2006) and GABA-ergic (Gonzalez-Burgos and Lewis, 2008) neurotransmitter 56 systems. The diverse psychopathology of schizophrenia cannot be explained by dysfunction 57 of neurotransmitter systems when considered in isolation (Keshavan et al., 2011) . Adenosine, 58 a homeostatic neuromodulator, is an emerging candidate neurobiological substrate with 59 effects on multiple neurotransmitter pathways (Boison, 2008; Cunha and Cunha, 2001) . In 60 addition, adenosine plays an important role in early brain development and regulation of 61 brain immune responses (Cunha and Cunha, 2001) , and thereby could also contribute to the 62 neurodevelopmental deviations implicated in schizophrenia (Lara et al., 2006) . 63
Adenosine deaminase (ADA) is a purine-inactivating endoenzyme that irreversibly 64 deaminates adenosine to inosine (Yegutkin, 2008) , leading to its final degradation to uric 65 acid. Like adenosine, ADA too is ubiquitously found in the human body (Franco et al., 1997) 66 and hence implicated in diverse physiological functions. Thus, serum ADA level has been 67 suggested as an important peripheral biomarker of adenosine signaling in neuropsychiatric 68 disorders (Elgün et al., 1999; Herken et al., 2007; Stubbs et al., 1982) especially in 69 schizophrenia, given that a hypoadenosinergic state has been linked to its pathogenesis (Lara 70 et al., 2006) . 71
In support of the above, Dutra et al. (Dutra et al., 2010) demonstrated lower frequency of 72 occurrence of an ADA variant with decreased enzymatic activity (G/A genotype) among 73 patients with schizophrenia, suggesting increased levels of ADA and reduced levels of 74 ambient adenosine. Another study reported significantly higher serum ADA in patients with 75 schizophrenia on antipsychotic monotherapy (more so with atypical antipsychotic), when 76 compared to healthy control subjects (Brunstein et al., 2007) , but found no correlation with 77 clinical psychopathology. However, Ghaleiha et al. (Ghaleiha et al., 2011) , reported that in 78 patients with chronic schizophrenia, antipsychotic therapy (particularly with clozapine) was 79 associated with an increase in serum ADA and symptomatic improvement. Therefore, it is 80 unclear whether the increased serum ADA reported in the above studies was the consequence 81 of treatment with antipsychotics or a marker of the disorder per se. 82 Therefore, we examined whether serum ADA levels were significantly different in patients 83 with schizophrenia who have never been exposed to antipsychotic medications in comparison 84 to matched healthy comparison subjects. In accordance with the proposed adenosine theory 85 of schizophrenia pathophysiology, we hypothesized that the serum ADA will be significantly 86 higher in patients with schizophrenia. We also aimed at exploring the hitherto unreported 87 relationship between serum ADA and symptom severity scores. 88
Materials and Methods
89
The study was carried out at the National Institute The healthy comparison subjects were recruited from the community through word-of-mouth. 118
They were screened to exclude past history of Axis I psychiatric disorders, personal history 119 of psychoactive medication use and family history of schizophrenia spectrum disorders in 120 first-degree relatives using a study-specific proforma. 121
All participants were screened to exclude history of significant head injury, neurological 122 disorders, medical conditions including acute infections, autoimmune disorders, endocrine 123 disorders, specific sleep disorders, and substance abuse including caffeine (daily intake of 124 caffeine-containing beverages and food substances exceeding 300mg/day). All were free of 125 any drugs known to affect immune or endocrine function. All participants underwent clinical 126 screening to rule out any unstable medical conditions. The participants were instructed to 127 avoid food and caffeine for at least 3 hours before the evening blood sample, following which 128 they had their dinner; overnight fasting was ensured before drawing the morning blood 129 sample. The above precautionary measures were adopted to avoid any confounding effects, 130
including that of food and caffeine on the measured ADA levels. 131
Measurement of ADA
132
Blood samples were collected from participants before and after their sleep as there was no 133 available evidence from the literature regarding the most appropriate time to collect serum for 134 ADA assay. The first sample was collected around 7p.m. (before dinner and before sleep) 135 similar to a previous schizophrenia study (Brunstein et al., 2007) and the second sample 136 around 7a.m. the following morning (after sleep and before breakfast) similar to earlier 137 studies in major depression (Elgün et al., 1999; Herken et al., 2007 Later both the samples were centrifuged for 10 minutes at 4000rpm to extract the serum. The 143 serum samples were then coded and stored in microtubes (Eppendrof Inc.) at -80 o Celsius for 144 the assay. 145
The ADA assay from serum was performed using a previously validated (Al-Rubaye and 146
Morad, 2012, 2013) colorimetric sandwich-enzyme immunoassay kit E91390Hu96 (USCN 147
Life Science Inc., Wuhan), following the instructions provided in the manual ("SEB390Hu-148 96 ELISA Kit for Adenosine Deaminase (ADA) -Instruction manual," 2012). All samples 149
were analyzed in duplicate and the intra-assay variability was less than 10%. Assays were 150 conducted at the Department of Neurochemistry under the supervision of S.S. The trained 151 neurochemist who carried out the assays was blinded to the study group status of the blood 152 samples. 153
Genotyping of ADA polymorphism 154
The ADA 22G>A polymorphism (rs73598374) was genotyped using allele-specific 155 polymerase-chain reaction under the supervision of M.P and S.J. Genotyping was done for 32 156 (HS=16; SZ=16) out of the 35 subjects, all of whom were found to have the G/G genotype. 157
Therefore, any further examination of the relationship between the ADA rs73598374 158 genotypes and serum ADA levels and the differences between patients with schizophrenia 159 and healthy comparison subjects was not possible in our limited sample. 160
Statistical analysis
161
Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software, Inc.) and 162
Statistical Toolbox of MATLAB 2012b (Mathworks, USA (ADAeven, ADAmorn and ADAdiff(even-morn)) with duration of illness, positive symptom scores 174
and negative symptom scores within the schizophrenia group. Spearman rank order 175 correlation test was used for the within-group correlations between ADA levels and age. All 176 the SAPS and SANS sub-scores (including their total scores) were included in the correlation 177 analysis, and thus 11 correlations were made for each ADA level (ADAeven, ADAmorn and 178 ADAdiff(even-morn)). To exclude accidental significance associated with multiple correlations, a 179 threshold value of 0.735 was set for the absolute correlation co-efficients (α=0.05; n=11) 180 using G*power 3.1 software (Faul et al., 2009 (Faul et al., , 2007 in order to obtain a statistical power 181 greater than 80% (Sabri et al., 1997) . All tests were assessed using two-tailed p values. 182
Results
183
In the two-way ANOVA, significant main effects were noted only for the group factor, while 184 there were no time effects or group x time interactions (Table 1) . On further exploring the 185 group difference, patients with schizophrenia showed significantly higher ADAeven ( Fig.1A;  186 t=2.66, p=0.013) and ADAmorn ( Fig.1B; t=3 and SAPS sub-scores to explore the relationship, if any, between symptom severity and ADA 195 levels ( Table 2) . A significant positive correlation was noted between ADAdiff(even-morn) and 196
hallucination sub-score of SAPS ( Fig.2B; n=11pairs , r=0.810, p=0.003) at the a-priori-197
decided significance threshold to account for multiple comparisons (see Statistical analysis 198 subsection). However, there was a high negative correlation nearing significance between 199
ADAdiff(even-morn) and avolition-apathy sub-score of SANS ( Fig.2C; n=11pairs , r=-0.717, 200 p=0.013). A positive trend was observed between ADAeven and hallucination sub-score of 201 SAPS (n=11pairs, r=0.601, p=0.050) while ADAmorn showed a trend for a positive correlation 202
with avolition-apathy sub-score of SANS (n=16pairs, r=0.500, p=0.049). 203 ADA levels were not found to be significantly correlated with age in HS (ADAeven:  204 n=17pairs, r=-0.092, p=0.727; ADAmorn: n=18pairs, r=-0.363, p=0.139) and in SZ (ADAeven: 205 n=11pairs, r=0.097, p=0.777; ADAmorn: n=16pairs, r=-0.190, p=0.481). ADA levels were also 206 not significantly correlated with duration of illness in the SZ (ADAeven: n=11pairs, r=-0.044, 207 p=0.897; ADAmorn: n=16pairs, r=-0.047, p=0.862). 208
Discussion
209
The present study found significantly higher serum ADA levels at two different time points 210 (7p.m. on day1 and 7a.m. on day2) in patients with recent-onset schizophrenia who had never 211 been exposed to neuroleptic medications, in comparison to matched healthy comparison 212
subjects. The study also provides evidence for a link between ADA levels and 213 psychopathology in patients with schizophrenia. Though, as a group, patients with schizophrenia had significantly higher ADA at both time 234
points, there was indeed wide variability of ADA values within and between the two time 235 points (Fig. 1B) . This might reflect the within-group differences in severity of the various 236 psychopathological dimensions. Interestingly we found a significant positive correlation 237
between ADAdiff(even-morn) and auditory hallucinations and a trend towards an inverse 238 correlation between ADAdiff(even-morn) and avolition-apathy. The positive correlation between 239
higher ADAeven (relative to ADAmorn) and auditory hallucinations ( Fig. 2A and 2B) ADAeven) and avolition-apathy ( Fig. 2A and 2C ) might reflect the hypoadenosinergic state 245 during night causing disrupted sleep, leading on to lethargy and avolition during day time. 246
These findings would therefore provide additional support to the possibility of a 247 hypoadenosinergic state (Boison, 2011; Lara et al., 2006) mediating the predominant 248 symptom dimensions of schizophrenia. 249
As mentioned in the Introduction, adenosine deaminase (ADA) is primarily responsible for 250 catalyzing the irreversible deamination of adenosine to inosine. At least two isoenzymes of 251 ADA viz., ADA1 and ADA2 are identified in humans (Ratech et al., 1981) . While these 252
isoenzymes are present in several tissues, they differ in their kinetic properties and tissue 253 distribution. ADA1 is mostly intracellular or on the cell membrane in the ecto-form, attached 254 to dipeptidyl peptidase 4 (Fan et al., 2012) . On the other hand, ADA2 is the main isoenzyme 255 in the serum. While ADA1 is expressed in lymphocytes and macrophages, ADA2 is more 256 abundant in the blood, brain and liver (Rosemberg et al., 2007) . Previous studies cited earlier 257 (e.g., Brunstein et al., 2007; Ghaleiha et al., 2011) have also assayed serum levels of ADA as 258 a surrogate marker for ADA levels in the brain. 259
It is pertinent to mention at this juncture that adenosine and other nucleosides are transported 260
across the blood-brain barrier via a saturable, carrier mediated mechanism (Kalaria and 261
Harik, 1988). The increased ADA activity in the periphery, as seen in patients with drug 262 naïve schizophrenia, may result in reduction of the circulatory levels of adenosine. This may 263 decrease the transport across the blood-brain barrier (BBB) leading to a hypoadenosinergic 264 state in the CNS. However, this speculation requires confirmation with additional 265 experiments involving the quantitation of adenosine and its metabolites (inosine, 266 hypoxanthine) in serum and CSF by HPLC method and measuring the isoform specific 267 enzyme activity in the serum and CSF. 268
It may be argued that the higher ADA found in our patient sample may be a compensatory 269 phenomenon secondary to a state-dependent increase in brain adenosine levels during the 270 psychotic state (Cunha and Cunha, 2001; Hirayama et al., 2011; Reddy et al., 1992) . 271
However, this argument fails to explain the overall ADA rise noted even among patients with 272 the negative symptom of avolition-apathy. As our patient group comprised of subjects with 273 heterogeneous symptom dimensions ( Fig. 2A) , it is unlikely that the higher ADA could have 274 exclusively resulted from higher state-dependent adenosine levels. Thus, the increased ADA 275 levels detected in our sample of patients with schizophrenia may be considered as a 276 peripheral marker of a hypoadenosinergic state that characterizes the disorder. Similarly, 277 medication induced elevation of serum ADA reported by Ghaleiha et al. (2011) in patients 278
with schizophrenia could be compensatory to an improvement in adenosinergic tone 279 associated with successful treatment. It has to be stated that these are indeed preliminary 280 hypotheses generated from the results of the study, which need to be tested in future studies 281 with larger sample sizes. 282
Adenosine has been shown to serve a regulatory function in the immune system of brain 283 (Haskó et al., 2005) . Though general immunological disorders were ruled out in all our 284 subjects through careful history and routine clinical hematological and biochemical screening 285 investigations, we did not carry out screening blood investigations to rule out autoimmune 286
conditions. Although remote associations between acute psychotic states, encephalitis and 287
NMDA auto-antibodies have been reported (Deakin et al., 2014), schizophrenia has not been 288 conclusively shown to be an autoimmune disorder (Coutinho et al., 2014) . Therefore, it is 289 unlikely that the raised ADA levels observed in our sample of patients with schizophrenia 290 could be secondary to an autoimmune state. 291
A potential limitation of the study is the fact that only protein levels of ADA in serum were 292 measured, while enzymatic activity of ADA was not assayed. While measuring the enzyme 293 activity offers greater correlation with physiological response, the practical difficulties in 294
handling the samples prompted us to measure the ADA protein levels. In our earlier pilot 295 studies, we observed a gradual decrease in the ADA enzyme activity when the serum samples 296
were stored at 4 o C or when subjected to two freeze-thaw cycles. However, as expected, the 297 ADA protein content remained unaltered upon storage/ freeze thawing. The present study 298 involved the recruitment of drug naïve subjects with schizophrenia over a substantial time 299
period. The samples were collected as and when the subjects were recruited and the serum 300 separated and stored. To avoid inter-assay variation, all the samples were analyzed at the 301 same time. In order to avoid any bias in the results due to varying lengths of sample storage, 302
it was considered appropriate to measure the protein content. Moreover, ADA also has 303 significant non-enzymatic actions (protein-protein interactions) with respect to desensitizing 304 and enhancing functionality of adenosine receptors (Ciruela et al., 2010; Gracia et al., 2008) . 305 Therefore, a protein level assessment may be a better indicator of the full range of ADA 306 activity in comparison to enzyme activity. 307
Finally, in our limited sample of neuroleptic-naïve patients with recent-onset schizophrenia 308 and matched healthy comparison subjects, all the genotyped subjects (HS=16; SZ=16) were 309 found to have G/G genotype of the ADA 22G>A polymorphism (rs73598374); none of the 310 subjects had the G/A genotype that is associated with lower ADA activity (Bachmann et al., 311 2012; Battistuzzi et al., 1981) . Larger samples of schizophrenia and healthy subjects may be 312 needed to observe between-group differences, if any, of the G/G and G/A genotypes as 313 reported in one previous study (Dutra et al., 2010) . Nevertheless, since all our subjects were 314 homogeneous with respect to the ADA 22G>A functional polymorphic variation, it may be 315 inferred that our observation of higher serum ADA levels in patients with schizophrenia is 316 unlikely to be confounded by genotypic variation between the study samples. 317
Conclusion
318
To the best of our knowledge, this is the first report of elevated serum ADA levels at two 319 time points in neuroleptic-naïve patients with recent-onset schizophrenia. Further, the study 320 also provides preliminary evidence for a link between ADA levels at different time points 321 with positive and negative symptoms of schizophrenia. These findings may be considered 322 strong evidences in support of the adenosine hypothesis of schizophrenia. In the background 323 of previous reports suggesting a possible genetic basis for the elevated ADA activity in 324 schizophrenia and the observation of alteration of ADA levels with successful treatment, the 325 potential utility of serum ADA levels as a biomarker or endophenotype of schizophrenia 326 should be researched in future studies. 327 6. Acknowledgments: 328 We would like to thank Mrs. Ammu Lukose (for recruitment and evaluation of subjects), Dr. with symptom severity of patients with schizophrenia [n=11]. Note that patients with higher 510 evening rise in ADA (shown in red) have higher hallucination scores, while those with higher 511 morning rise in ADA (shown in blue) have higher avolition-apathy scores. Line graph 512
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